SULM – Schweizerische Union für Labormedizin | Union Suisse de Médecine de Laboratoire | Swiss Union of Laboratory Medicine

Sie sind hier | Vous êtes ici:

Z Romic1 , Lj Mayer1 , J Lovrecek1 , B Vitunjski-Englert1 , B Jeren2 , B Vurusic3 , B Conkas3 , J Lazic4 , Z Fejes5 , J Lovcic5

1Department of Laboratory Diagnosis, Dubrava University Hospital, Zagreb, Croatia, 2Department of Haemodialysis, Dubrava University Hospital, Zagreb, Croatia, 3County Hospital Cakovec, Croatia, 4Public Health Center Sesvete, Croatia, 5Bjelovar General Hospital, Croatia

B-type natriuretic peptide is a sensitive marker of heart failure, especially left ventricular disfunction. In this study, 250 patients with end stage renal disease were included. They were all divided into three groups according to the ethiopathogenesis of the disease: D-diabetic; C-cardiopatic, and O-others. The concentration of BNP was measured in the sample of heparinised plasma using Abbot test kits. In all off the studied groups, BNP concentration was significantly higher than in healthy persons. We noted the biggest rise in group C, which was according to expected. Median value of the concentrations measured in that group was 1329 pg/mL. To some extent, the surprise was the rise of BNP plasma concentration in groups D (1074 pg/mL) and O (485 pg/mL). In group C BNP was significantly higher in comparison with groups D (p < 0,05) and O (p < 0,0001). That could be another proof for the possible use the of this parameter as the prognosis and stratification factor in cardiovascular complications in hemodialysied patients. Additional use of determinating BNP concentration, according to the litterature data, could be the assessement of survival (mortality risk) of hemodialysied patients.


07. & 08.03.2019: Swiss eHealth Forum - Digitales Gesundheitswesen – Hope and > mehr


pipette 06/2018: Die Analyse der Darmflora | Analyse du microbiote

Aktuelle Ausgabe als E-Paper lesen


17.12.2018: Cheflaboranten/in 80%, (HFR) Tafers